Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7RNPJ)

• Drug Name: Trenonacog alfa Drug Info
• Synonyms: IB-1001; IXinity; Nonacog-alfa biosimilar - Emergent BioSolutions; Nonacog-alfa biosimilar - Inspiration; Recombinant factor IX biosimilar - Emergent BioSolutions; Recombinant factor IX biosimilar - Inspiration

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Discontinued in Phase 3	[1]

• Cross-matching ID: TTD Drug ID: DM7RNPJ

Molecule-Related Drug Atlas

Drug(s) Targeting Coagulation factor IX (F9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Emicizumab	DM0AQ83	Factor VIII deficiency	3B10	Approved	[2]
Recombinant Factor IX	DMY7ESM	Bleeding disorder	GA20-GA21	Approved	[3]
CSL-654	DMZJGVL	Factor IX deficiency	3B11	Phase 3	[4]
RG6013	DMER75Y	Haemophilia A	3B10.0	Phase 3	[5]
AMT-061	DMSO02K	Haemophilia B	3B11.0	Phase 3	[6]
Fidanacogene elaparvovec	DMFZ81T	Haemophilia B	3B11.0	Phase 3	[7]
Mim8	DMX33ZR	Haemophilia A	3B10.0	Phase 3	[8]
TTP889	DMCQARM	Blood forming organ disorder	JB64.1	Phase 2	[9]
AMT-060	DM7RNKM	Factor IX deficiency	3B11	Phase 1/2	[10]
SB-FIX	DMUP52Y	Haemophilia B	3B11.0	Phase 1/2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Coagulation factor IX (F9)	TTFEZ5Q	FA9_HUMAN	Modulator	[1]

References

• [1] Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis.Haemophilia.2012 Nov;18(6):881-7.
• [2] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [3] BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B. Ther Adv Hematol. 2014 Oct;5(5):168-80.
• [4] Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012 September 20; 120(12): 2405-2411.
• [5] Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014 Feb;12(2):206-13.
• [6] Clinical pipeline report, company report or official report of uniQure.
• [7] Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua. J Thromb Haemost. 2021 May;19(5):1212-1218.
• [8] ClinicalTrials.gov (NCT05878938) Open-label Safety Study in Adults and Adolescents With Haemophilia A With and Without FVIII Inhibitors Switching Directly From Emicizumab Prophylaxis to NNC0365-3769 (Mim8) Prophylaxis. U.S.National Institutes of Health.
• [9] Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost. 2008 Mar;6(3):457-63.
• [10] Phase I/II clinical trial of AMT-060 for treating hemophilia B. uniQure N.V.
• [11] ClinicalTrials.gov (NCT02695160) Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B. U.S. National Institutes of Health.